‘Painkiller’ or the voracity of a pharmaceutical company
The Netflix series about Purdue Pharma and OxyContin is a perfect example of corporate greed: anything goes if the bottom line is positive

The creators of Netflix drama Painkiller, a powerful denunciation of the pharmaceutical company Purdue Pharma and its star drug, the analgesic OxyContin, cover their backs from hypothetical responsibilities by including relatives of real victims of the highly addictive opioid in each episode. The production stresses that “although the series is based on real events,” some characters and dialogues are the result of fiction, something perfectly understandable and dubiously justifiable, and which sounds like a legal recommendation.
In any case, the series is a perfect example of corporate voracity: anything goes if the bottom line is positive, and so it must have been when the U.S. Supreme Court blocked the bankruptcy agreement that the pharmaceutical company filed in 2019, in a maneuver to protect members of the Sackler family, its owners, from lawsuits filed by thousands of opioid addiction victims in exchange for a $6 billion compensation package. Of course, the huge sales and vast profits derived from the painkiller would not have been possible without the cooperation of hundreds — perhaps thousands — of doctors who prescribed it without a second thought.
A chilling fact: the death toll from OxyContin is estimated at 500,000, a figure known to Richard Sackler, the president of Purdue Pharma, played by an undaunted Matthew Broderick. Painkiller is a remarkable series, created by Micah Fitzerman-Blue and Noah Harpster, that connects with the self-critical capacity that the powerful American audiovisual industry occasionally shows.
Sign up for our weekly newsletter to get more English-language news coverage from EL PAÍS USA Edition
Tu suscripción se está usando en otro dispositivo
¿Quieres añadir otro usuario a tu suscripción?
Si continúas leyendo en este dispositivo, no se podrá leer en el otro.
FlechaTu suscripción se está usando en otro dispositivo y solo puedes acceder a EL PAÍS desde un dispositivo a la vez.
Si quieres compartir tu cuenta, cambia tu suscripción a la modalidad Premium, así podrás añadir otro usuario. Cada uno accederá con su propia cuenta de email, lo que os permitirá personalizar vuestra experiencia en EL PAÍS.
¿Tienes una suscripción de empresa? Accede aquí para contratar más cuentas.
En el caso de no saber quién está usando tu cuenta, te recomendamos cambiar tu contraseña aquí.
Si decides continuar compartiendo tu cuenta, este mensaje se mostrará en tu dispositivo y en el de la otra persona que está usando tu cuenta de forma indefinida, afectando a tu experiencia de lectura. Puedes consultar aquí los términos y condiciones de la suscripción digital.
More information
Archived In
Últimas noticias
Chris Martin, Taylor Swift, Elijah Wood and other famous wedding ‘crashers’
‘How does it feel to be a failure?’: Elizabeth Berkley’s journey from ‘Showgirls’ ridicule to vindication
The story of the Málaga virus: The code that haunted Google’s cybersecurity center director for 30 years
The impact of Ecuador’s mega-prison: A polluted river, cleared forests and military checkpoints
Most viewed
- Christian Louboutin: ‘Young people don’t want to be like their parents. And if their parents wear sneakers, they’re going to look for something else’
- The low-cost creative revolution: How technology is making art accessible to everyone
- All the effects of gentrification in one corner of Mexico’s Colonia Roma
- Liset Menéndez de la Prida, neuroscientist: ‘It’s not normal to constantly seek pleasure; it’s important to be bored, to be calm’
- December Social Security and SSI payments: Dates, double checks and the 2026 COLA increase











































